Market Overview

UPDATE: Citigroup Reiterates Medtronic at Buy Following Kanghui Holdings Deal

Share:
Related MDT
Following Intuitive Surgical's Solid Q2, Citi Asks What's Next
Medtronic Gets First-Ever FDA Approval For Cement-Augmented Pedicle Screws
T. Rowe Price Buys Apple, Pepsi, Western Digital (GuruFocus)

Citigroup maintained its Buy rating on Medtronic (NYSE: MDT) as the company announced the acquisition of Kanghui Holdings (NYSE: KH), thus likely ending its current joint venture with Chinese firm Weigao.

Citigroup noted, "KH is expected to generate $65MM in annual sales in 2012 with growth in excess of 20%. Trauma is 60% of sales and spine is around 33%. The sales level is similar to MDT's current run rate of sales from the Weigao JV but has a higher trauma and lower recon mix. MDT has an option to acquire Weigao's 49% stake in the JV by May 2013 for a range of $450-725MM or the JV would expire in January 2014. Since MDT paid more for KH, we assume either the management fit and/or product mix are considered preferable."

Medtronic closed at $43.48 on Thursday.

Latest Ratings for MDT

DateFirmActionFromTo
Jun 2016SunTrust Robinson HumphreyMaintainsBuy
Jun 2016Guggenheim SecuritiesInitiates Coverage onNeutral
Jun 2016Deutsche BankMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color News Reiteration M&A Intraday Update Analyst Ratings

 

Related Articles (MDT + KH)

View Comments and Join the Discussion!